Khalid Shah
Harvard medical School, USA
Biography
Khalid Shah heads the Molecular Neurotherapy and Imaging Laboratory in the departments of Radiology and Neurology at Massachusetts General Hospital. Dr. Shah is also the Director of the Stem Cell Therapeutics and Imaging program in the Center for Translational Research at MGH and also a Principal Faculty at Harvard Stem Cell Institute in Boston. His laboratory focuses on developing therapeutic stem cells for receptor targeted therapies for cancer and testing their efficacy in clinically relevant mouse tumor models. Dr. Shah’s research also explores the development of novel in vivo imaging markers and their potential use in assessing fate of stem cells and their therapeutic efficacy. In recent years, Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. In an effort of to translate the exciting therapies develped in his laboratory into clinics, he has recently founded biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.
Abstract
Abstract : Stem cell based therapies for cancer: mechanism and translation into clinics